In the US, Ibrutinib (ibrutinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Chronic Lymphocytic Leukemia, Graft-versus-host disease, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma and Waldenström Macroglobulinemia.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Tyrosine kinase inhibitor
- Ibrutinibum (Latin)
- Ibrutinib (German)
- Ibrutinib (French)
- Ibrutinib (Spanish)
- Ibrutinib (OS: USAN, JAN)
- UNII-1X70OSD4VX (IS)
- Ibrutinib (PH: JP XVI)
Catalent CTS, Israel; Janssen, Ireland; Janssen, Slovenia; Janssen, Slovakia; Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag, United Kingdom; Janssen-Cilag, Poland; Johnson & Johnson, Croatia (Hrvatska); Pharmacyclics, United States
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.